Deleterious aberrations in DNA repair genes are actionable in approximately 25% of
metastatic castration-resistant prostate cancers (mCRPC) patients. Homology recombination …

Current treatment for patients with metastatic hormone-sensitive prostate cancer (mHSPC)
delays disease progression and improves survival, but resistance is inevitable. Additional …

Comprehensive genomic studies have delineated key driver mutations linked to disease
progression for most cancers. However, corresponding transcriptional changes remain …

Background Until five years ago, the metastatic hormone-sensitive prostate cancer (mHSPC)
treatment landscape was dominated by the use of androgen deprivation therapy (ADT) …

Purpose The epithelial-to-mesenchymal transition (EMT) is a fundamental process in tumor
progression that endows cancer cells with migratory and invasive potential. Snail, a zinc …

Background In metastatic hormone-sensitive prostate cancer (mHSPC) treatment, survival
benefits have been shown by adding docetaxel or recent androgen receptor axis-targeted …

Standard treatment for metastatic castration-sensitive prostate cancer (mCSPC) was
androgen-deprivation therapy (ADT) for> 7 decades, and this was termed the “all-comers” …

Simple Summary Prostate cancer research has been recently characterized by the discovery
of several prognostic and predictive molecular factors, which ultimately improve patients' …

Background Both Docetaxel (DOC) and Abiraterone (ABI) improve the survival of men with
metastatic, castration sensitive prostate cancer (mCSPC). However, the outcome among …

Patients with prostate cancer (PCa) will eventually progress to castrate-resistant prostate
cancer (CRPC) after androgen deprivation therapy (ADT) treatment. Prostate-specific …